Literature DB >> 11474775

Novel direct curve comparison metrics for bioequivalence.

J E Polli1, A M McLean.   

Abstract

PURPOSE: The object of this work was to devise four new direct curve comparison (DCC) metrics and examine each metric's distribution properties and performance characteristics.
METHODS: DCC metrics, Cmax, and AUCi were calculated from two bioequivalence studies of three sustained release carbamazepine formulations, where a range of profile similarity was observed. DCC metric values and their confidence intervals were compared to Cmax and AUCi.
RESULTS: The DCC metrics rho, rhom, deltaa, and deltas, exhibited more favorable distributions than Cmax and AUCi ratios, which were frequently skewed. The DCC metrics performed differently than Cmax and AUCi ratios in profile comparisons due to the nature of the DCC metrics. Unlike Cmax and AUCi, the DCC metrics utilize all data points to directly compare entire profiles. Each DCC metric appears to measure "exposure" in a single assessment. Possible bioequivalence acceptance criteria are: p < or =1.40, rhom, < or =0.35, deltaa, < or =0.27, and deltas < or =0.102.
CONCLUSIONS: These DCC metrics, particularly rhom, are promising bioequivalence metrics for "exposure."

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474775     DOI: 10.1023/a:1011067908500

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Bioequivalence.

Authors:  A Rescigno
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

2.  An alternative approach for assessment of rate of absorption in bioequivalence studies.

Authors:  M L Chen
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

3.  Comparison of absorption rates in bioequivalence studies of immediate release drug formulations.

Authors:  R Schall; H G Luus
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-05

4.  Absorption rate vs. exposure: which is more useful for bioequivalence testing?

Authors:  T N Tozer; F Y Bois; W W Hauck; M L Chen; R L Williams
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

5.  Is Cmax/AUC useful for bioequivalence testing?

Authors:  A Rostami-Hodjegan; G T Tucker
Journal:  J Pharm Sci       Date:  1997-12       Impact factor: 3.534

6.  Secondary metrics for the assessment of bioequivalence.

Authors:  L Endrenyi; L Tothfalusi
Journal:  J Pharm Sci       Date:  1997-03       Impact factor: 3.534

7.  The multivariate assessment of bioequivalence.

Authors:  V M Chinchilli; R K Elswick
Journal:  J Biopharm Stat       Date:  1997-03       Impact factor: 1.051

8.  Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets.

Authors:  J E Polli; G S Rekhi; L L Augsburger; V P Shah
Journal:  J Pharm Sci       Date:  1997-06       Impact factor: 3.534

9.  Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.

Authors:  L F Lacey; O N Keene; C Duquesnoy; A Bye
Journal:  J Pharm Sci       Date:  1994-02       Impact factor: 3.534

10.  Metrics comparing simulated early concentration profiles for the determination of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; M L Chen
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more
  6 in total

1.  Biometrical evaluation of bioequivalence trials using a bootstrap individual direct curve comparison method.

Authors:  E Zintzaras; P Bouka; A Kowald
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

2.  Statistical aspects of bioequivalence testing between two medicinal products.

Authors:  E Zintzaras
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

3.  When is a metric not a metric? Remarks on direct curve comparison in bioequivalence studies.

Authors:  Wojciech Jawień
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-21       Impact factor: 2.745

4.  Dissolution comparisons using a Multivariate Statistical Distance (MSD) test and a comparison of various approaches for calculating the measurements of dissolution profile comparison.

Authors:  J-M Cardot; B Roudier; H Schütz
Journal:  AAPS J       Date:  2017-03-28       Impact factor: 4.009

5.  Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate.

Authors:  Jeanne Fourie Zirkelbach; Andre J Jackson; Yaning Wang; Donald J Schuirmann
Journal:  Pharm Res       Date:  2012-09-25       Impact factor: 4.200

6.  Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical-driven balance of population average and variability.

Authors:  Sara Soufsaf; Fahima Nekka; Jun Li
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.